Xavier University of Louisiana

The Administrators of the Tulane Educational Fund

United States of America, As Represented by the Secretary of Agriculture

United States Department of Agriculture

Xavier University

Quan Jiang

Guangdi Wang

Matthew E Burow

Stephen M Boue

Shilong Zheng

Qiu Zhong

Qiang Zhang

Thomas E Wiese

Bruce Alan Bunnell

Amy Strong

Disclosed are daidzein analogs having the formula (I). Also disclosed are compositions, include a disclosed daidzein analogs, methods of preventing or treating bone disease or bone injury and/or stimulating bone growth, in a subject that include administering to the subject an effective amount of disclosed daidzein analog. Disclosed are isolated mesenchymal stem cell that has been altered by treatment a disclosed daidzein analog, daidzein, glycinol, glyceollin I, or glyceollin II, to increase the osteogenic potential of the mesenchymal stem cells.

Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells

Provided are compositions for treatment of cancers, including breast cancer, comprising at least one novel daidzein analog, as well as methods of using the same for preventing or treating cancer or tumor growth.

Daidzein analogs as treatment for cancer

Thiazole analog compounds and their pharmaceutically acceptable salts are disclosed, including pharmaceutical compositions comprising the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, and/or with a pharmaceutically acceptable carrier. Methods of using the thiazole analog compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative diseases, such as cancer, are also disclosed.

Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease

The present disclosure relates to boron-based 4-hydroxytamoxifen and endoxifen prodrugs and the synthesis of the same. Further, the present disclosure teaches the utilization of the boron-based 4-hydroxytamoxifen and endoxifen prodrugs in a treatment for breast cancer.

Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer

Growing community of inventors

New Orleans, LA, United States of America

Quan Jiang